What is HC Wainwright’s Forecast for Longeveron Q1 Earnings?

Longeveron Inc. (NASDAQ:LGVN) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Longeveron in a report released on Monday, March 3rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.31) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Longeveron’s Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.20) EPS.

Several other research analysts also recently weighed in on the company. Roth Capital upgraded Longeveron to a “strong-buy” rating in a research note on Thursday, December 5th. Roth Mkm initiated coverage on shares of Longeveron in a research report on Friday, December 6th. They set a “buy” rating and a $10.00 target price for the company.

Longeveron Trading Down 3.6 %

Shares of NASDAQ LGVN opened at $1.33 on Wednesday. The firm has a market cap of $19.73 million, a price-to-earnings ratio of -0.21 and a beta of 0.36. The stock has a fifty day simple moving average of $1.65 and a two-hundred day simple moving average of $1.90. Longeveron has a 1-year low of $0.77 and a 1-year high of $6.40.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after buying an additional 97,953 shares in the last quarter. Virtu Financial LLC purchased a new stake in Longeveron in the 4th quarter worth approximately $53,000. Jane Street Group LLC purchased a new stake in Longeveron in the 4th quarter worth approximately $35,000. Northern Trust Corp bought a new position in Longeveron in the 4th quarter valued at $31,000. Finally, State Street Corp purchased a new position in shares of Longeveron during the 3rd quarter valued at $29,000. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.